ERBB2 and neoplasm: Given our findings that T-MMAE selectively radiosensitized HER2 expressing cancer cells, we decided to evaluate the more immediate clinical potential of our strategy by testing if T-DM1 radiosensitized tumours in a HER2+ selective manner.